PDE5A and Alzheimer disease: Considering RUT containing a quinoline structure, which has been demonstrated to be a privileged structure for the PDE5 inhibitor (Bi et al., 2004), Huang et al. decided to use RUT as the lead compound to develop PDE5 inhibitors for the treatment of AD (Huang et al., 2020).